The Uneasy Partnership Between Biotech Research Groups and Tech Transfer Offices at German Universities

Almost every founding team I work with that emerged from a German university lab tells a version of the same story: the science worked, the excitement was real, and then the process of actually getting the intellectual property out of the university and into a company took far longer, and involved far more friction, than anyone anticipated. This is not a story about bad actors. It is a story about two institutions with genuinely different incentive structures being forced to collaborate on something neither is fully built for.

Two different clocks

A biotech research group runs on the clock of publication and grant renewal. A PI's career depends on output that is visible, citable, and timely. A PhD student's thesis has a defined end date regardless of where the IP conversation stands. The scientific incentive is to publish the result as soon as it is defensible — and publication, once it happens, starts a novelty-destroying clock on patentability under the European Patent Convention's absolute novelty requirement (Art. 54 EPC). There is no grace period in Europe the way there is, conditionally, in the US under 35 U.S.C. § 102(b). Once it is public, it is public everywhere, permanently, for patent purposes.

A Tech Transfer Office runs on an entirely different clock: invention disclosure review, freedom-to-operate assessment, prior art search, patent filing strategy, and — critically — the search for a licensee or spin-off team willing to carry commercialisation risk. None of that happens in the weeks a nervous PhD student has before a conference submission deadline. Most TTOs at German universities are working through a queue of disclosures with a small, generalist staff covering every faculty from mechanical engineering to immunology. A biotech-specific patent claim, with its own dense prior art landscape and its own regulatory pathway considerations, does not get a biotech specialist's attention by default — it gets whoever on the team has bandwidth that quarter.

The Arbeitnehmererfindungsgesetz backdrop

The legal foundation matters more here than in most countries. Under the German Act on Employees' Inventions (Arbeitnehmererfindungsgesetz, ArbnErfG), inventions made by university researchers in the course of their employment belong, by default, to the university — a position reinforced since the 2002 abolition of the "Hochschullehrerprivileg" that previously let professors retain their own IP. Researchers are obligated to disclose inventions (§ 5 ArbnErfG), and the university has a limited window to decide whether to claim them (§ 6). If it claims the invention, the researcher is entitled to statutory compensation once it is commercialised (§ 42 ArbnErfG for university inventions specifically), typically around 30 percent of licensing or sale proceeds after cost deduction.

That structure is reasonable on paper. In practice, it means every invention disclosure is, from day one, a negotiation with unclear timelines, unclear valuation, and a compensation formula that researchers rarely understand until it becomes relevant — usually at exactly the moment they are trying to convince outside investors that the IP position is clean and freely licensable.

Where the friction actually shows up

Disclosure timing versus publication pressure. Researchers under-disclose or disclose late because the TTO process feels slow relative to their publication timeline, and because the incentive to publish is immediate while the incentive to protect IP is abstract until someone wants to build a company around it. By the time that someone shows up, the novelty-destroying publication may already have happened.

Valuation and licensing terms that do not match early-stage reality. A TTO negotiating a license for a pre-clinical biotech asset is working from a playbook often shaped by experience across all faculties, not biotech-specific norms around royalty stacking, milestone structuring, or the realistic 8–12 year runway to any revenue-generating event in drug or diagnostic development. Terms that would be normal for a mature licensing deal can be genuinely unworkable for a pre-seed spin-off that has not raised a euro yet.

Equity and founder capacity get treated as secondary to IP terms, when in early-stage biotech they are often the more decisive variable. A spin-off with clean, workable IP terms but a founding team without the operational and regulatory experience to execute is not more likely to succeed than one with slightly worse terms and a team that actually knows how to run a GLP study or navigate an early regulatory strategy conversation. TTOs are, understandably, optimised to protect the university's IP position — that is their mandate — but IP protection and startup viability are not the same objective, and treating them as interchangeable produces spin-offs that are legally clean and commercially fragile.

What genuinely helps

Engaging the TTO before the result is publishable, not after. The earlier a PI brings a TTO into the loop — even informally, even before the invention is fully disclosure-ready — the more runway exists to align the publication timeline with a provisional filing. Most TTOs will move faster for a researcher who engages early and repeatedly than for one who shows up with a paper already submitted.

Bringing in someone who has run the commercialisation side before, not to replace the TTO relationship but to translate between the two worlds. A researcher and a TTO officer are both making reasonable decisions from within their own incentive structure; what is usually missing is someone who has been on the founding team side of a biotech spin-off and can help frame the disclosure, the licensing ask, and the equity conversation in terms that make sense commercially, not just legally.

Using EXIST and comparable pre-seed instruments deliberately, not as an afterthought. The BMWK's EXIST-Forschungstransfer programme exists precisely to bridge the gap between an academic result and a fundable company, funding up to €250,000 in personnel and material costs over 18 months plus coaching. Teams that plan their TTO negotiation and their EXIST application in parallel, rather than sequentially, generally reach a workable spin-off structure faster than teams that treat licensing as a solved problem before applying.

None of this is a criticism of TTOs as institutions. They are working with limited headcount against an increasing volume of disclosures, and a mandate — protecting institutional IP — that is neither wrong nor optional. But research groups that understand the TTO's actual constraints, and engage early enough to work with the process rather than against its clock, consistently end up with better spin-off outcomes than those who treat tech transfer as a bureaucratic hurdle to clear at the last possible moment.

---

If you are navigating a spin-off from a German university lab and the tech transfer conversation feels slower or more opaque than the science warrants, that gap is usually closeable with the right framing early on. I work with founding teams to bridge exactly this — get in touch if you are in the middle of it.